VBI Vaccines Inc. (VBIV): history, ownership, mission, how it works & makes money (2024)

A Brief History of VBI Vaccines Inc. (VBIV)

VBI Vaccines Inc. is a biopharmaceutical company focused on the development of novel vaccines for infectious diseases. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

• 2011: VBI Vaccines Inc. was founded with the mission to develop innovative vaccines to address unmet medical needs.
• 2015: The company went public, trading on the NASDAQ under the ticker symbol VBIV.
• 2018: VBI Vaccines Inc. launched its lead product candidate, Sci-B-Vac, a third-generation hepatitis B vaccine.
• 2019: The company entered into a research collaboration with GlaxoSmithKline to develop a vaccine targeting the respiratory syncytial virus (RSV).
• 2020: VBI Vaccines Inc. announced positive results from a Phase 1/2a study of its cytomegalovirus (CMV) vaccine candidate.
• 2021: The company initiated a Phase 3 clinical study of Sci-B-Vac for the prevention of hepatitis B.

Who Owns VBI Vaccines Inc. (VBIV)

VBI Vaccines Inc. is a biopharmaceutical company that focuses on the development of vaccines for infectious diseases and immune-oncology. The company was founded in 2001 and is headquartered in Cambridge, Massachusetts.

The ownership of VBI Vaccines Inc. is primarily held by institutional investors, with the largest shareholders being Vanguard Group, BlackRock Inc., and State Street Corporation. These institutional investors hold significant stakes in the company and play a key role in its corporate governance and decision-making processes.

Individual investors also own a portion of VBI Vaccines Inc., although their ownership is typically smaller in comparison to institutional investors. These individual investors include retail investors, high-net-worth individuals, and company executives who may have received shares as part of their compensation packages.

• Vanguard Group: Vanguard Group is one of the largest investment management companies in the world and holds a substantial stake in VBI Vaccines Inc.
• BlackRock Inc.: BlackRock Inc. is another major institutional investor that owns a significant portion of VBI Vaccines Inc.
• State Street Corporation: State Street Corporation is a financial services company that also has a notable ownership stake in VBI Vaccines Inc.

Overall, VBI Vaccines Inc. is primarily owned by institutional investors like Vanguard Group, BlackRock Inc., and State Street Corporation, with individual investors also holding a smaller percentage of ownership. These stakeholders play a crucial role in shaping the direction and future of the company.

VBI Vaccines Inc. (VBIV) Mission Statement

At VBI Vaccines Inc., our mission is to develop novel vaccines to address unmet medical needs and improve the lives of patients around the world. We are committed to leveraging our innovative science and technology to create safe and effective vaccines that can protect against a wide range of infectious diseases.

Our primary focus is on developing vaccines for infectious diseases such as hepatitis B, cytomegalovirus (CMV), and glioblastoma. We strive to advance cutting-edge vaccine candidates through clinical trials and regulatory approvals to bring them to market as quickly as possible.

We are dedicated to collaborating with healthcare professionals, regulators, and global partners to accelerate the development and distribution of our vaccines. By working together, we aim to make a meaningful impact on public health and contribute to the global effort to control and eradicate infectious diseases.

Key elements of our mission include:

• Developing safe and effective vaccines
• Addressing unmet medical needs
• Advancing innovative science and technology
• Collaborating with healthcare professionals and global partners
• Improving public health outcomes

How VBI Vaccines Inc. (VBIV) Works

VBI Vaccines Inc. (VBIV) is a biopharmaceutical company that is focused on the development of innovative vaccines to address unmet medical needs. The company uses a unique approach to vaccine design, known as the enveloped virus-like particle (eVLP) platform, which allows for the development of vaccines for a wide range of infectious diseases.

The process of how VBI Vaccines Inc. works involves several key steps:

• Research and Development: VBI Vaccines Inc. has a team of scientists and researchers who are dedicated to identifying and developing new vaccine candidates. They leverage the eVLP platform to create vaccines that mimic the structure of viruses, without the genetic material that causes disease.
• Clinical Trials: Once a vaccine candidate has been identified, VBI Vaccines Inc. conducts clinical trials to evaluate the safety and efficacy of the vaccine. These trials are typically conducted in multiple phases, with each phase designed to gather additional data on the vaccine's performance.
• Regulatory Approval: After completing clinical trials, VBI Vaccines Inc. submits the necessary data to regulatory agencies for approval. If the vaccine is deemed safe and effective, it can receive regulatory approval for commercialization.
• Commercialization: Once a vaccine has been approved, VBI Vaccines Inc. works to bring the vaccine to market. This may involve partnerships with other companies for distribution, marketing, and sales.

How VBI Vaccines Inc. (VBIV) Makes Money

VBI Vaccines Inc. (VBIV) is a biopharmaceutical company that generates revenue through various channels in the healthcare industry. The following are some of the key ways in which VBI Vaccines Inc. makes money:

• Sales of Commercial Vaccines: One of the primary sources of revenue for VBI Vaccines Inc. is the sale of commercial vaccines. The company develops and markets vaccines for the prevention of infectious diseases, generating revenue through the sale of these products to healthcare providers and governments.
• Research and Development Collaborations: VBI Vaccines Inc. also generates revenue through research and development collaborations with pharmaceutical companies, academic institutions, and government agencies. These collaborations involve the sharing of resources and expertise in the development of new vaccines and technologies, with VBI Vaccines Inc. receiving payments and royalties for its contributions.
• Licensing Agreements: Another way in which VBI Vaccines Inc. makes money is through licensing agreements with other companies. The company may license its technologies, intellectual property, or products to third parties in exchange for upfront payments, milestone payments, and royalties on future sales.
• Government Contracts and Grants: VBI Vaccines Inc. also generates revenue through government contracts and grants for the development of vaccines for public health initiatives. The company may receive funding from government agencies such as the National Institutes of Health (NIH) or the Centers for Disease Control and Prevention (CDC) to support its research and development efforts.